Inhibrx Biosciences, Inc. INBX
We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential.
On May 29, 2024, Inhibrx, Inc., or the Former Parent, effected the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency, upon which the Former Parent completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of our common stock, or the Distribution. On May 30, 2024, the Former Parent completed a series of internal restructuring transactions, or the Separation.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $1.3M | $200.0K | $1.8M | — |
| R&D | $113.0M | $203.7M | $191.6M | — |
| SG&A | $23.3M | $127.9M | $29.4M | — |
| Total operating expenses | $136.3M | $331.6M | $221.0M | — |
| Operating income | -$135.0M | -$331.4M | -$219.2M | — |
| Interest expense | $12.2M | $13.5M | $31.8M | — |
| Pre-tax income | -$140.1M | $1.69B | -$239.7M | — |
| Income tax | $2.0K | $2.0K | $3.0K | — |
| Net income | -$140.1M | $1.69B | -$241.4M | — |
| EPS, basic | -9.04 | 114.01 | -20.48 | — |
| EPS, diluted | -9.04 | 112.62 | -20.48 | — |
| Shares, diluted (wtd. avg.) | $15.5M | $15.0M | $11.8M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $124.2M | $152.6M | $277.9M | $273.9M |
| Total current assets | $132.8M | $160.4M | $295.4M | — |
| Property, plant and equipment | $3.7M | $6.2M | $6.4M | — |
| Total assets | $146.5M | $180.8M | $307.9M | — |
| Accounts payable | $5.9M | $9.2M | $11.0M | — |
| Total current liabilities | $33.8M | $40.7M | $56.3M | — |
| Long-term debt | $100.6M | $0 | $207.0M | — |
| Total liabilities | $138.5M | $47.2M | $264.4M | — |
| Retained earnings | -$246.2M | -$106.1M | -$613.7M | — |
| Total equity | $8.0M | $133.6M | $43.5M | $58.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$129.8M | -$194.4M | -$193.3M | — |
| Depreciation and amortisation | $2.5M | $2.3M | $1.2M | — |
| Stock-based compensation | $11.1M | $58.5M | $24.8M | — |
| Capital expenditure | $31.0K | $2.6M | $4.6M | — |
| Investing cash flow | -$28.0K | -$2.6M | -$4.6M | — |
| Financing cash flow | $101.4M | $71.7M | $202.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0002007919-26-000006.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |